Search results

Rich countries must open the way to cheaper mass-produced COVID-19 vaccines in order to protect every person in the world and avert a $9 trillion “worst case” global economic catastrophe, said Oxfam today. They should also agree this week to inject $650 billion more into the global economy to help developing countries cope with the pandemic’s already devasting effects.

Survivors of COVID-19 from 37 countries are among almost 1,000 people who have signed an open letter to pharmaceutical industry leaders calling for a ‘people's vaccine’ and treatments that are available to all – free from patents. The letter comes on the eve of a high-level side event about the pandemic at the UN General Assembly in New York.

One year on from the declaration of the COVID-19 pandemic, the People’s Vaccine Alliance is warning that developing countries are facing critical shortages of oxygen and medical supplies to cope with COVID-19 cases yet the majority have been unable to administer a single dose of a COVID-19 vaccine. In contrast rich nations have vaccinated their citizens at a rate of one person per second over the last month.

Two-thirds of countries are yet to meet the target of vaccinating 70 percent of people in all countries against COVID-19 set a year ago at the UN General Assembly, according to figures published today by Oxfam and The People’s Vaccine Alliance.

The European Parliament has supported an amendment calling for Europe to support the temporary suspension of intellectual property rules for Covid-19 vaccines, tests, and treatments. In reaction to this vote, Evelien van Roemburg, head of Oxfam EU office, said: "This vote sends a strong signal that Europeans stand shoulder to shoulder with the people of the world in the fight against the pandemic."

Campaigners from the People’s Vaccine Alliance say the refusal of pharmaceutical companies to openly share their vaccine science and technology and the lack of action from rich countries to ensure access to vaccines globally have created the perfect breeding ground for new variants such as Omicron.

Responding to the announcement that COVAX has received more funding and is planning to accelerate its vaccine rollout, Oxfam International’s Head of Inequality Policy, Max Lawson, said: “More funding for COVAX and a quicker rollout of vaccines is a small piece of good news for developing countries struggling to get the doses they need, but at best fewer than a quarter of people in these countries will have been vaccinated by the end of the year."

More than a million people have died from COVID since G7 leaders last met back in February, when they made vague pledges to increase the global vaccine supply, but crucially failed to collectively back the waiver of intellectual property rules and investment in manufacturing vaccines in developing countries that would really make the difference.

Responding to the announcement that BioNTech plans to ship mobile vaccine factory containers to Africa, which could start producing vaccines in the second half of 2023, Oxfam’s Health Policy Manager, Anna Marriott, said:  “Efforts to boost vaccine manufacturing in Africa are welcome but this is a long-term project and should not distract from the failure of rich country governments and companies, including Germany and BioNTech, to tackle today’s shameful vaccine inequality responsible for millions of needless deaths in poorer countries from this pandemic.